Features Feed for Tickers
Seattle company gets green light for human tests on potential COVID-19 cure – WPEC – CBS 12
The FDA has approved the new trial for the joint venture between Seattle’s Infectious Disease Research Institute and New Jersey’s Celularity Inc., which has pioneered an investigational immunotherapy, the companies say.
“The treatment is based on the administration of immune cells known as Natural Killer or ‘NK cells’ which have been safely given in early phase studies to patients for the treatment of leukemia and multiple myeloma,” IDRI officials said in a press release announcing the trial’s approval. “NK cells play a key role in the body’s defense against viral infections, and the severe cases of COVID-19 in the initial patients were associated with low NK cell counts.”
The study will enroll 100 patients who have been diagnosed with pneumonia caused by COVID-19, the study authors said. Those patients will be provided an infusion of the new treatment.
